Literature DB >> 16849454

The cytoplasmic domain of Fas ligand costimulates TCR signals.

Mingyi Sun1, Kristina T Ames, Ivy Suzuki, Pamela J Fink.   

Abstract

Productive T cell activation generally requires costimulation in addition to a signal delivered through the TCR. Although FasL is well-characterized for its capacity to deliver a death signal through Fas, this TNF family member can also transmit a reverse signal to enhance Ag-driven T cell proliferation. In this study, we define this reverse signal through FasL as costimulation by showing it requires TCR coengagement and is CD28 independent. We demonstrate that FasL-mediated costimulation drives FasL recruitment into lipid rafts and association with select Src homology 3 (SH3)-containing proteins. We further show that the proline-rich intracellular domain of FasL is sufficient to costimulate by enhancing the phosphorylation of Akt, ERK1/2, JNK, and FasL itself, by activating the transcription factors NFAT and AP-1, and by enhancing IFN-gamma production. These results elucidate the pathway of costimulation through the death inducer FasL, and comprise the first mechanistic analysis of a newly emerging group of costimulators, the TNF family.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849454     DOI: 10.4049/jimmunol.177.3.1481

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Stimulation of FasL induces production of proinflammatory mediators through activation of mitogen-activated protein kinases and nuclear factor-κB in THP-1 cells.

Authors:  Sang-Min Lee; Eun-Ju Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  Engineering macrophages to control the inflammatory response and angiogenesis.

Authors:  K V Eaton; H L Yang; C M Giachelli; M Scatena
Journal:  Exp Cell Res       Date:  2015-11-21       Impact factor: 3.905

3.  Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts.

Authors:  Huan-Ching Lin; Po-Yin Lai; Yu-ping Lin; Jyun-Yuan Huang; Bei-Chang Yang
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

4.  Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells.

Authors:  Douglas V Dolfi; Alina C Boesteanu; Constantinos Petrovas; Dong Xia; Eric A Butz; Peter D Katsikis
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

5.  Cell death-associated ADAMTS4 and versican degradation in vascular tissue.

Authors:  Richard D Kenagy; Seung-Kee Min; Alexander W Clowes; John D Sandy
Journal:  J Histochem Cytochem       Date:  2009-06-08       Impact factor: 2.479

6.  Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.

Authors:  Thomas Kolben; Udo Jeschke; Toralf Reimer; Nora Karsten; Elisa Schmoeckel; Anna Semmlinger; Sven Mahner; Nadia Harbeck; Theresa M Kolben
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

7.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Exposure to inorganic mercury in vivo attenuates extrinsic apoptotic signaling in Staphylococcal aureus enterotoxin B stimulated T-cells.

Authors:  Michael D Laiosa; Kevin G Eckles; Margaret Langdon; Allen J Rosenspire; Michael J McCabe
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-19       Impact factor: 4.219

Review 9.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

10.  Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening.

Authors:  Matthias Voss; Marcus Lettau; Ottmar Janssen
Journal:  BMC Immunol       Date:  2009-10-06       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.